Search Results
In Loving Memory of a Cancer-Fighting Legacy: UFCW Fights Cancer in Honor of Late Staff Member
The United Food and Commercial Workers (UFCW) is one of North America’s largest labor organizations with more than 1.3 million members.
One Family’s Inspiring Quest to Help Other Families Impacted By Cancer
A nasty cough and extreme fatigue first led Myrna and Lou Binder to bring their 12-year-old son, Jeff, to the doctor for an examination. But the flu-like symptoms persisted until more tests enabled the doctors to arrive at the shocking diagnosis: non-Hodgkin lymphoma. The year was 1975.
CAR-T Pioneer Dr. Carl June Elected to the U.S. National Academy of Science
The Leukemia & Lymphoma Society (LLS) congratulates Carl June, MD, of the University of Pennsylvania, whose groundbreaking research ushered in a new era in cancer immunotherapy, for his election into the U.S. National Academy of Science (U.S. NAS). Dr. June earned this prestigious honor through recognition by his peers for his “distinguished and continuing achievements in original research.”
3 Insights from a Clinical Trial Patient
The road to finding new and better cancer treatments often includes an important step: clinical trials. For patients with hard-to-treat diseases, these studies can be superhighways to the right treatment. A clinical trial can tell oncologists whether a new treatment works, how certain cancer types affect the body, and more.
Moms In Training: Keeping on Track
Staying on track while you train for a walk or run event can be challenging at times. This is especially true for busy moms who barely have enough time to work out, let alone track their fitness progress.
Coming Soon: A Brave New World
Research is inching us closer to cures for blood cancer every day – among them, therapies that unleash the immune system, reprogramming of T-cells to track down cancer cells, and personalized treatments based on a patient’s genetic make-up.
Mechlorethamine gel
Mechlorethamine gel is FDA approved for the treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Rasburicase
Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.
Bleomycin
Bleomycin is FDA approved as a single agent or in proven combinations to treat people who have Hodgkin and non-Hodgkin lymphoma. Bleomycin may cause a temporary loss of hair in some people. Normal hair growth should return after treatment ends (although it may take several months).
Copanlisib
Copanlisib is FDA approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
The First Official Day of #ASH15
Beat AML is a collaboration launched nearly three years ago by LLS and the Knight Cancer Institute at Oregon Health & Science University (OHSU), to go on the offenensive against acute myeloid leukemia (AML), a blood cancer with a poor prognosis and little change in the standard of care in 40 years. More than a dozen abstracts from the first phase of the initiative will be featured throughout the American Society of Hematology (#ASH15) Annual Meeting in Orlando over the next few days.
Paying Tribute to a Legacy: Executive Challenge Winners Recognized
This year’s Light The Night Executive Challenge ended with a bittersweet roundup of results. The winner, Stacey Weathers, former long-time executive director of The Leukemia & Lymphoma Society’s (LLS) New Jersey chapter, was tragically killed this past October when a tree fell on her car during a storm. Even though she isn’t here to celebrate with her LLS colleagues and family, her worthy achievement will be recognized as her legacy lives on.
A Powerful Force
Nutrition Advice from a Dietitian & Blood Cancer Survivor
76-year-old Barbara Borrell is a woman who wears many hats – a 50+ year registered dietitian, nutrition consultant and educator, cancer advocate, volunteer with The Leukemia & Lymphoma Society, and a blood cancer survivor who has battled not one, not two, but three types of blood cancer.
Cancer Wasn’t Going to Stop Me
When I entered Rutgers University, I thought, “This is the beginning of the rest of my life.” Little did I know that virtually my entire college career I would be battling cancer.
I was sick and had mono symptoms at least twice a month my entire freshman year, developed a lump on my neck the fall semester of my sophomore year, and after a surgery to remove the lump, was diagnosed with Hodgkin lymphoma. I just turned 20 and I had cancer. I thought my life was over. I kept thinking, “What was I going to do about school?”
Lomustine
Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who relapse while being treated with primary therapy or who fail to respond to primary therapy.
Plerixafor
Plerixafor injection is FDA approved for use along with a granulocyte colony-stimulating factor (G-CSF) medication in preparation for an autologous stem cell transplant in patients with non-Hodgkin lymphoma or myeloma. Plerixafor injection works by causing certain blood cells to move from the bone marrow to the blood so that they can be removed for transplantation.
High School Student Proves Youngest Generation Can Make an Impact on Cancer Research and Cures
Ella Behnke of San Antonio, Texas, is a 16-year-old cheerleader who attends Alamo Heights High School and is making history, as the winner of The Leukemia & Lymphoma Society’s (LLS) national title “Student of the Year.” Ella raised more than $334,768 for LLS to invest in cancer cures with an intense seven-week fundraising campaign involving everything from a very active campaign team, social media activations to visiting cancer patients at the Children’s Hospital of San Antonio.